Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Phase of Trial: Phase IV
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Therapeutic Use
- 09 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.